HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Sertraline Hydrochloride

HCID 63009
New reaction
Print
Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
79559-97-0
Standard SMILES
CN[C@H]1CC[C@@H](c2ccc(Cl)c(Cl)c2)c2ccccc21.Cl
InChIKey
BLFQGGGGFNSJKA-XHXSRVRCSA-N
Molecular formula
C17H18Cl3N
Average molar mass
342.7 g/mol
Monoisotopic mass
341.05048262

Overview

Sertraline hydrochloride is a hydrochloride resulting from the reaction of equimolar amounts of sertraline and hydrogen chloride. A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder. It has a role as an antidepressant and a serotonin uptake inhibitor. It contains a sertraline(1+).

Names & identifiers

Preferred name
Sertraline Hydrochloride
IUPAC
(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine;hydrochloride
English name
Sertraline hydrochloride
Molecular formula
C17H18Cl3N
Molecular weight
342.69

Names & synonyms

Sertraline hydrochloride79559-97-0Sertraline HCl(+)-sertraline hydrochlorideDTXSID1040243Sertraline (as hydrochloride)NSC-746308NSC-758948UTI8907Y6XCP-51974-1CHEBI:9124DTXCID9020243
Show more names
SETRALINE HCLSERTRALINE MANDELATESertraline hydrochloSertraline hydrochloride impurity standardN-(4(3,4-DICHLOROPHENYL)-3,4-DIHYDRO-1(2H)NAPHTHALIDENE) METHANAMINE(1S,4S)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPHTHALENAMINE HYDROCHLORIDE(1S,4S)-4-(3,4-Dichlorophenyl)-N-Methyl-1,2,3,4-tetrahydronaphthalen-1-aMine hydrochlorideCP-51974-1 HCl(1s-cis)-lorid
1-Naphthalenamine, 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-, hydrochloride, (1S-cis)-BesitronRefChem:6216Hydrochloride, SertralineSertraline Hydrochloride (1S-cis)-ZoloftGlademSerad

Properties

Computed structural properties

Topological polar surface area
12 Ų
Hydrogen bond donors
2
Hydrogen bond acceptors
1
Rotatable bonds
2
Heavy atoms
21
Formal charge
0
Complexity
322

Experimental & physicochemical properties

Human Drugs · 2 items

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Collision Cross Section168.1 Ų [M+H]+ [CCS Type: TW; Method: calibrated with polyalanine and drug standards]

Physicochemical properties

Melting point
246 · 246-249°C
alpha
23 · D23 +37.9° (c = 2 in methanol)
Density
1.37 · 1.37
Flash point
9 ℃ · 9℃
storage temp.
2 · 2-8°C
solubility
26 mg/mL · DMSO: ~26 mg/mL
form
solid
pka
9.48 · pKa (water): 9.48 ± 0.04; pKa (methanol:water, 40:60 v/v): 8.6; pKa (ethanol:water, 1:1 v/v): 8.5(at 25℃)
color
white
optical activity
33 to · [α]/D +33 to +43°, c =2.0 in methanol
Merck
14 · 14,8467

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 4 items

Warning

H302 (99.1%): Harmful if swallowed [Warning Acute toxicity, oral]

P203, P264, P270, P273, P280, P301+P317, P318, P330, P391, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 116 reports by companies from 15 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Regulatory Information(+)-Sertraline hydrochloride: Does not have an individual approval but may be used under an appropriate group standard
Hazard Classes and CategoriesAcute Tox. 4 (99.1%)

Toxicology

Treatment · 1 item

Treatment should consist of those general measures employed in the management of overdosage with any antidepressant. Ensure an adequate airway, oxygenation and ventilation. Monitor cardiac rhythm and vital signs. General supportive and symptomatic measures are also recommended. Induction of emesis is not recommended. Gastric lavage with a large-bore orogastric tube with appropriate airway protection, if needed, may be indicated if performed soon after ingestion, or in symptomatic patients. Activated charcoal should be administered. Due to large volume of distribution of this drug, forced diuresis, dialysis, hemoperfusion and exchange transfusion are unlikely to be of benefit. No specific antidotes for sertraline are known. (L1712)

Exposure Routes · 1 item

The effects of food on the bioavailability of the sertraline tablet and oral concentrate were studied in subjects administered a single dose with and without food. For the tablet, AUC was slightly increased when drug was administered with food but the Cmax was 25% greater, while the time to reach peak plasma concentration (Tmax) decreased from 8 hours post-dosing to 5.5 hours. For the oral concentrate, Tmax was slightly prolonged from 5.9 hours to 7.0 hours with food.

Chemistry & industry

Pharmacology

Metabolism/Metabolites · 1 item

Extensively metabolized in the liver. Sertraline metabolism involves <i>N</i>-demethylation, <i>N</i>-hydroxylation, oxidative deamination, and glucuronidation of sertraline carbamic acid. Sertraline undergoes <i>N</i>-demethylation primarily catalyzed by cytochrome P450 (CYP) 2B6, with CYP2C19, CYP3A4 and CYP2D6 contributing to a lesser extent. Deamination occurs via CYP3A4 and CYP2C19. <i>In vitro</i> studies have shown that monoamine oxidase A and B may also catalyze sertraline deamination. Sertraline <i>N</i>-carbamoyl glucuronidation has also been observed in human liver microsomes. Route of Elimination: Sertraline is extensively metabolized and excretion of unchanged drug in urine is a minor route of elimination. Half Life: The elimination half-life of sertraline is approximately 25-26 hours. The elimination half-life of desmethylsertraline is approximately 62-104 hours.

FDA Pharmacological Classification · 4 items

SERTRALINE HYDROCHLORIDE

Cytochrome P450 2D6 Inhibitors [MoA]; Serotonin Reuptake Inhibitor [EPC]; Serotonin Uptake Inhibitors [MoA]

SERTRALINE HCL

Cytochrome P450 2D6 Inhibitors [MoA]; Serotonin Reuptake Inhibitor [EPC]; Serotonin Uptake Inhibitors [MoA]

MeSH Pharmacological Classification · 2 items

Mood-stimulating drugs used primarily in the treatment of affective disorders and related conditions. Several MONOAMINE OXIDASE INHIBITORS are useful as antidepressants apparently as a long-term consequence of their modulation of catecholamine levels. The tricyclic compounds useful as antidepressive agents (ANTIDEPRESSIVE AGENTS, TRICYCLIC) also appear to act through brain catecholamine systems. A third group (ANTIDEPRESSIVE AGENTS, SECOND-GENERATION) is a diverse group of drugs including some that act specifically on serotonergic systems.

Compounds that specifically inhibit the reuptake of serotonin in the brain.

Uses & manufacturing

Uses · 1 item

For the management of major depressive disorder, posttraumatic stress disorder, obsessive-compulsive disorder, panic disorder with or without agoraphobia, premenstrual dysphoric disorder, social phobia, premature ejaculation, and vascular headaches.

Related reactions

106 records
New reaction record
HRID 6377 reaction equation
HRID 6377As product
HRID 6378 reaction equation
HRID 6378As product
HRID 25350 reaction equation
HRID 25350As product
HRID 25351 reaction equation
HRID 25351As product
HRID 347400 reaction equation
HRID 347400As product
HRID 347401 reaction equation
HRID 347401As product
HRID 347402 reaction equation
HRID 347402As product
HRID 347403 reaction equation
HRID 347403As product
PreviousPage 1 of 14

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes

Database identifiers

CAS
79559-97-0、79617-89-3、79617-95-1
PubChem CID
63009
DTXSID
DTXSID1040243
ChEMBL
CHEMBL1709
ChEBI
CHEBI:9124
UNII
UTI8907Y6X
EC Number
616-702-0、616-708-3
Stability
Store in Freezer
InChI
InChI=1/C17H17Cl2N.ClH/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11;/h2-6,8,10,12,17,20H,7,9H2,1H3;1H/t12-,17-;/s3
InChIKey
BLFQGGGGFNSJKA-TYIRTQGFNA-N
SMILES
C12C=CC=CC=1[C@H](CC[C@H]2C1=CC=C(Cl)C(Cl)=C1)NC.Cl |&1:6,9,r|
CAS DataBase Reference
79559 · 79559-97-0(CAS DataBase Reference)
FDA UNII
8907 Y6X · UTI8907Y6X
NCI Drug Dictionary
sertraline hydrochloride
UNSPSC Code
41116107 · 41116107
NACRES
77 · NA.77
Symbol(GHS)
7 · GHS07,GHS09
Signal word
Warning
Hazard statements
302 · H302-H400
Precautionary statements
273 · P273-P301+P312+P330
PPE
95 · Eyeshields, Gloves, type N95 (US)
Hazard Codes
Xi,T,F
Risk Statements
36 · 36/37/38-39/23/24/25-23/24/25-11
Safety Statements
22 · 22-24/25-36-26-45-36/37-16-7
RIDADR
1230 · UN1230 - class 3 - PG 2 - Methanol, solution
WGK Germany
3 · 3
RTECS
352070 · QJ0352070
HazardClass
IRRITANT
HS Code
29214990 · 29214990
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
4 OralAquatic · Acute Tox. 4 OralAquatic Acute 1Aquatic Chronic 1STOT RE 2
Toxicity Summary · 1 item

The exact mechanism of action sertraline is not fully known, but the drug appears to selectively inhibit the reuptake of serotonin at the presynaptic membrane. This results in an increased synaptic concentration of serotonin in the CNS, which leads to numerous functional changes associated with enhanced serotonergic neurotransmission. It is suggested that these modifications are responsible for the antidepressant action observed during long term administration of antidepressants. It has also been hypothesized that obsessive-compulsive disorder is caused by the dysregulation of serotonin, as it is treated by sertraline, and the drug corrects this imbalance.

Signs and SymptomsSymptoms of toxicity include alopecia, decreased libido, diarrhea, ejaculation disorder, fatigue, insomnia, somnolence and serotonin syndrome.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 6 items

Drug Induced Liver Injury Rank (DILIrank 2.0)

Sertraline hydrochloride

vLess-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

Safety data

PPE
Eyeshields, Gloves, type N95 (US)
wgk
3
rtecs
QJ0352070
ridadr
UN1230 - class 3 - PG 2 - Methanol, solution
hs_code
29214990
risk_code
36/37/38-39/23/24/25-23/24/25-11
Signal word
Warning
Symbol(GHS)
GHS07,GHS09
hazard_code
Xi,T,F
safety_code
22-24/25-36-26-45-36/37-16-7
hazard_class
IRRITANT
Storage Class
11 - Combustible Solids
Hazard statements
H302-H400
Hazard Classifications
Acute Tox. 4 OralAquatic Acute 1Aquatic Chronic 1STOT RE 2
Precautionary statements
P273-P301+P312+P330
Applications · 8 items

DescriptionSertraline(79559-97-0) is the hydrochloride form of sertraliine. Sertraline belongs to the selective serotonin reuptake inhibitor (SSRI) class antidepressant drug. Sertraline is indicated for the treatment of major depressive disorder in adults as well as obsessive-compulsive disorder, post-traumatic stress disorder (PTSD), premenstrual dysphoric disorder (PMDD), panic disorder and social anxiety disorder occurring in both adults and children. Its exact mechanism of action is still not fully understand. But it is indicated that this drug can selectively inhibit the reuptake of serotonin at the presynaptic membrane, increasing serotonin levels in the synapses and enhancing serotonergic neurotransmission. This effect seems to be related to the antidepressant effect of sertraliine.

DescriptionSertraline is a selective serotonin reuptake inhibitor (SSRI). It inhibits monoamine uptake by the serotonin transporter (SERT) with an IC50 value of 70 nM. It is selective for SERT over the norepinephrine and dopamine transporters (IC50s = 520 and 720 nM, respectively). Sertraline (3.2-56 mg/kg, s.c.) reduces immobility in the forced swim test in mice. Sertraline (5 μM) prevents acid sphingomyelinase activation and subsequent ceramide release induced by infection with replication-deficient vesicular stomatitis virus pseudoviral particles (pp-VSV) presenting the severe acute respiratory coronavirus 2 (SARS-CoV-2) spike protein in Vero cells, an effect that can be overcome with exogenous application of C16 ceramide. Formulations containing sertraline have been used in the treatment of depression, obsessive-compulsive disorder (OCD), premenstrual dysphoric disorder (PMDD), and various anxiety disorders.

DescriptionSertraline hydrochloride is a selective serotonin reuptake inhibitor, similar mechanistically to fluoxetine, introduced initially for the maintenance and long-term treatment of depression. It is reportedly non-sedating and compared to fluoxetine has a shorter duration of action and lack of CNS activating effects such as nervousness and anxiety. Sertraline hydrochloride is currently undergoing investigation for the treatment of obesity and obsessive-compulsive disorders.

UsesA selective serotonin reuptake inhibitor. Used as an antidepressant

Usesantibacterial

UsesA selective ST inhibitor

UsesThe effect of exposure of sertraline hydrochloride was studied in chronically prepared ovine fetus. It was used in glucocorticoid function assay to study the effect of antidepressants on glucocorticoid receptor function in humans.

General DescriptionSertraline, marketed as the brand drug Zoloft, is an SSRI antidepressant used in the treatment of major depression as well as obsessive-compulsive, panic, and social anxiety disorders. This Certified Snap-N-Spike Solution is applicable for use in LC/MS or GC/MS applications for urine drug testing, clinical toxicology, and forensic analysis.

Upstream & downstream products

Upstream raw materials

Potassium tert-butoxideMethylamine3,4-DichlorobenzophenoneSertralineAluminum chlorideThionyl chloride3,4-Dichlorobenzoyl chlorideDiethyl succinateMandelic acidTitanium tetrachlorideHydrogenHydrogen bromideSodium chloride
Additional notes · 1 item

DefinitionChEBI: A hydrochloride resulting from the reaction of equimolar amounts of sertraline and hydrogen chloride. A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as an antidepressant for the treatment of depression, obsessive-compulsive diso der, panic disorder and post-traumatic stress disorder.